The deal follows a string of trials and settlements totaling $550 million in separate cases around the country.
Generic drug manufacturer Teva Pharmaceuticals would pay $4.25 billion to settle more than 2500 lawsuits with states, local governments, and tribes over its role in the opioid epidemic under a settlement announced late Tuesday.
Teva, based in Israel, was one of the largest makers of prescription painkillers at the peak of the opioid crisis. CDC data show the epidemic has claimed more than 932,000 US lives since 1999, including 69,000 in 2020.
The deal follows a string of trials and settlements totaling $550 million in separate cases around the country. It was announced by several state attorneys general who brokered the tentative agreement. A total of 12 states have taken part in the negotiations, according to a statement from California Attorney General Rob Bonta, who noted that talks between Teva and New York State continue.
The news was included in Teva's second-quarter results released Tuesday.
“This agreement is another major step toward addressing the opioid crisis and healing our communities,” Bonta said. “Nothing can undo the harm opioids makers like Teva have inflicted on families across the country or the lives lost to the opioid epidemic. But this agreement will provide much-needed relief for its victims and importantly, critical funds for overdose prevention and opioid addiction disorder treatment.”
Teva makes Actiq and Fentora, which are branded fentanyl products for cancer pain, as well as generic opioids that include oxycodone. The states claimed Teva had promoted rapid-onset fentanyl drugs for use outside cancer treatment, downplayed addiction risks, and failed to comply with suspicious order monitoring requirements.
States have the option of accepting supplies of naloxone, which can reverse an opioid overdose. The deal calls for Teva to provide up to $1.2 billion worth of generic naloxone, according to Bona’s statement.
The California official said that final settlement “remains contingent on agreement on critical business practice changes and transparency requirements.” Both Allergan, a generics manufacturer acquired by Teva, and various state governments must sign off on a final deal.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.